Explore
Validate
Learn
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [5]
- Comments [0]
- Validations
- Western blot [2]
- Immunohistochemistry [1]
- Flow cytometry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- ABIN2840693 - Provider product page
- Provider
- antibodies-online
- Product name
- anti-Cyclin E1 (CCNE1) (AA 373-402), (C-Term) antibody
- Antibody type
- Polyclonal
- Description
- This antibody is purified through a protein A column, followed by peptide affinity purification.
- Reactivity
- Human
- Host
- Rabbit
- Epitope
- AA 373-402, C-Term
- Antibody clone number
- RB07335
- Vial size
- 80 μL
- Storage
- Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Submitted references G1 arrest by p16INK4A uncouples growth from cell cycle progression in leukemia cells with deregulated cyclin E and c-Myc expression.
Down-regulation of BRCA1-BARD1 ubiquitin ligase by CDK2.
The structure of cyclin E1/CDK2: implications for CDK2 activation and CDK2-independent roles.
Patterns of cyclin E, retinoblastoma protein, and p21Cip1/WAF1 immunostaining in the oncogenesis of papillary thyroid carcinoma.
The tumor-specific hyperactive forms of cyclin E are resistant to inhibition by p21 and p27.
Ausserlechner MJ, Obexer P, Geley S, Kofler R
Leukemia 2005 Jun;19(6):1051-7
Leukemia 2005 Jun;19(6):1051-7
Down-regulation of BRCA1-BARD1 ubiquitin ligase by CDK2.
Hayami R, Sato K, Wu W, Nishikawa T, Hiroi J, Ohtani-Kaneko R, Fukuda M, Ohta T
Cancer research 2005 Jan 1;65(1):6-10
Cancer research 2005 Jan 1;65(1):6-10
The structure of cyclin E1/CDK2: implications for CDK2 activation and CDK2-independent roles.
Honda R, Lowe ED, Dubinina E, Skamnaki V, Cook A, Brown NR, Johnson LN
The EMBO journal 2005 Feb 9;24(3):452-63
The EMBO journal 2005 Feb 9;24(3):452-63
Patterns of cyclin E, retinoblastoma protein, and p21Cip1/WAF1 immunostaining in the oncogenesis of papillary thyroid carcinoma.
Brzeziński J, Migodziński A, Toczek A, Tazbir J, Dedecjus M
Clinical cancer research : an official journal of the American Association for Cancer Research 2005 Feb 1;11(3):1037-43
Clinical cancer research : an official journal of the American Association for Cancer Research 2005 Feb 1;11(3):1037-43
The tumor-specific hyperactive forms of cyclin E are resistant to inhibition by p21 and p27.
Wingate H, Zhang N, McGarhen MJ, Bedrosian I, Harper JW, Keyomarsi K
The Journal of biological chemistry 2005 Apr 15;280(15):15148-57
The Journal of biological chemistry 2005 Apr 15;280(15):15148-57
No comments: Submit comment
Supportive validation
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- WB
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- WB
Supportive validation
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- IHC
Supportive validation
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- FACS
